PuraPharm (HKSE:01498) COGS-to-Revenue : 0.51 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PuraPharm COGS-to-Revenue?

PuraPharm's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$107.1 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$211.8 Mil.

PuraPharm's COGS to Revenue for the six months ended in Dec. 2023 was 0.51.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. PuraPharm's Gross Margin % for the six months ended in Dec. 2023 was 49.44%.

PuraPharm COGS-to-Revenue Historical Data

The historical data trend for PuraPharm's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm COGS-to-Revenue Chart

PuraPharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.43

0.39

0.36

0.41

0.47

PuraPharm Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.36	0.35	0.48	0.43	0.51

PuraPharm COGS-to-Revenue Calculation

PuraPharm's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	190.23	/	406.859
	=	0.47

PuraPharm's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	107.074	/	211.778
	=	0.51

PuraPharm (HKSE:01498) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

PuraPharm's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	107.074 / 211.778
	=	49.44 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

PuraPharm COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of PuraPharm's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PuraPharm (HKSE:01498) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG

Website

https://www.purapharm.com

PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.

PuraPharm (HKSE:01498) Headlines

No Headlines